THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2018

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2018

WEBINARS

Register Now and
On Demand

Home » Archive by Tags

Articles tagged with: Qiagen

Qiagen, Natera to develop genetic testing assays, 5/18

May 2018—Qiagen and Natera will partner to develop cell-free DNA assays, including for prenatal screening, for use on the Qiagen GeneReader NGS System.

Qiagen offers AdnaTest for lung, prostate cancers

April 20, 2018—Qiagen launched two liquid biopsy panels to evaluate circulating tumor cells in prostate and lung cancers. The AdnaTest …

IGRAs for immigration TB screening, 4/18

April 2018—The U.S. Centers for Disease Control and Prevention issued a notification to U.S. civil surgeons stating it will require the use of FDA-approved interferon gamma release assays for tuberculosis screening. The CDC plans for the changes to medical screening guidelines to go into effect Oct. 1.

CDC to use IGRAs for immigration TB screening

Feb. 28, 2018—The U.S. Centers for Disease Control and Prevention issued a notification to U.S. civil surgeons stating it will …

Qiagen to buy Stat-Dx

Feb. 20, 2018—Qiagen has entered into an agreement to acquire Stat-Dx, a developer of molecular diagnostics systems, for $147 million. …

Qiagen, DiaSorin partnership, 2/18

February 2018—Qiagen and DiaSorin announced a partnership in which Qiagen’s QuantiFeron-TB diagnostic test will be added to the menu of DiaSorin’s Liaison family of analyzers, enabling customers of both companies to process QuantiFeron-TB Gold Plus, a fourth-generation assay for latent tuberculosis detection, on Liaison platforms. QFT-Plus is the first assay from the QuantiFeron portfolio that is planned to be adapted for use on the Liaison systems, with additional assays under consideration.

Qiagen, Centogene join forces on rare disease testing, 1/18

January 2018—Qiagen and Centogene announced a collaboration and comarketing agreement to provide customers more complete sample-to-insight research and clinical testing solutions in rare genetic diseases. The collaboration includes the integration of Centogene’s CentoMD rare disease variant database into Qiagen’s bioinformatics offering to enhance test interpretation.

Qiagen, Centogene join forces on rare disease testing

Oct. 17, 2017—Qiagen and Centogene announced a collaboration and comarketing agreement to provide customers more complete sample-to-insight …

Qiagen joins Cancer-ID consortium, 8/17

August 2017—Qiagen has joined Cancer-ID, a public-private consortium of 36 partners from 13 countries that aims to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.

Qiagen launches JAK2 test

April 17, 2017—Qiagen launched its Ipsogen JAK2 RGQ PCR Kit, which was cleared by the Food and Drug Administration as …

X